Y-mAbs(YMAB) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase ● Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong ● Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter ...